PDCA管理模式在中成药类辅助用药监控管理中的应用分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application of PDCA management mode in the monitoring and management of Chinese patent medicine auxiliary drugs.Methods PDCA cycle management method was used to summarize the current status of the use of proprietary Chinese medicines, summarize problems, find out the reasons, formulate intervention targets and measures, and conduct irrational drug intervention.Statistical analysis was carried out on the use of proprietary Chinese medicines before the implementation of PDCA cycle management (from January to December in 2017)and PDCA cycle management (from January 2018 to June 2019) in our hospital to evaluate the intervention effect and form a normalized management mechanism.Results Since the implementation of PDCA cycle management in 2018, the sales amount of proprietary Chinese medicines in our hospital and its proportion of total sales of medicines had shown a downward trend.The sales amount in 2018 (1152.61 million yuan) was higher than that in 2017 (1931.71 million yuan).The decline was 40.34%.In 2018, the proportion of sales to total sales of medicines (5.05%) decreased by 41.69%compared with 2017 (8.66%).In the first half of 2019, it maintained a downward trend in 2018, reaching the expected intervention target.Conclusion PDCA cycle management can effectively reduce the use of Chinese medicines in hospitals, reduce the burden of patients' drug costs, and promote rational drug use.

Key words： PDCA Circulation Adjuvant drug Drug intervention Aational drug use Sales amount

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Hui-fen
	OU Huan-jiao

Cite this article:

ZENG Hui-fen,OU Huan-jiao. Application analysis of PDCA management mode in the monitoring and management of Chinese patent medicine auxiliary drugs[J]. 中国当代医药, 2020, 27(11): 183-186.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I11/183

[1]	国家食品药品监督管理总局国家药品不良反应监测中心.《国家药品不良反应监测年度报告（2016年）》[S].2017-04-28.
[2]	杨静，郑磊，陈莉，等.我院辅助治疗药物临床使用管理模式的建立[J].中国药房，2017，28（25）：3545-3548.
[3]	国家卫生计生委国家中医药局.《关于印发进一步改善医疗服务行动计划的通知》（国卫医发〔2015〕2号）[S].2015-01-12.
[4]	国家卫生和计划生育委员会，国家发展和改革委员会，财政部，等.《关于印发控制公立医院医疗费用不合理增长的若干意见的通知》（国卫体改发〔2015〕89号）[S].2015-10-27.
[5]	广东省卫生计生委，广东省发展改革委，广东省财政厅，等.《关于印发控制公立医院医疗费用不合理增长的实施方案的通知》（粤卫办〔2016〕100号）[S].2016-09-18.
[6]	广东省卫生和计划生育委员会.《广东省卫生计生委办公室关于建立全省医疗机构重点药品监控制度的通知》（粤卫办〔2017〕74号）[S].2017-12-12.
[7]	中山市卫生和计划生育委员会.《关于进一步规范医疗机构辅助用药管理的通知》[S].2017-10-26.
[8]	刘书伟.我院辅助用药应用管理模式的探讨[J].海峡药学，2018，30（5）：285-286.
[9]	孙道开.医院辅助治疗用药的管理模式探讨[J].医药导报，2014，33（1）：128-129.
[10]	郑利光，施祖东，赵电红，等.实施PDCA循环管理前后医院辅助用药应用分析及管理效果探讨[J].中国医院用药评价与分析，2018，18（5）：687-690.
[11]	国家卫生健康委办公厅，国家中医药局办公室.《关于印发第一批国家重点监控合理用药药品目录（化药及生物制品）的通知》（国卫办医函〔2019〕558号）[S].2019-6-11.
[12]	国家卫生健康委办公厅.《国家三级公立医院绩效考核操作手册（2019版）》[S].2019-5-22.
[13]	饶媚，赖小卿，蒋建清.我院辅助用药使用情况及其超说明书用药医嘱审核与干预[J].海峡药学，2017，29（9）：79-84.
[14]	杨飞，刘飞.医疗机构辅助用药管理的实践与思考[J].农垦医学，2016，38（1）：38-40.
[15]	刘叶芳，马玉琴.药学干预对辅助药品合理应用的影响[J].医药导报，2017，36（增刊）：111-114.